# A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX

> **NCT00002340** · PHASE3 · COMPLETED · sponsor: **Glaxo Wellcome** · enrollment: 615 (—)

## Conditions studied

- Pneumonia, Pneumocystis Carinii
- HIV Infections

## Interventions

- **DRUG:** Atovaquone
- **DRUG:** Pentamidine isethionate

## Key facts

- **NCT ID:** NCT00002340
- **Lead sponsor:** Glaxo Wellcome
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 615 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002340, "A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*